1. Scrip
  2. >>Focus On Asia
  3. >>Japan

Zelboraf, Cosentyx and Takecab Set For Japan Listing, Launch

 
• By Ian Haydock

Japan's granting of reimbursement prices to a batch of new drugs including Chugai's Zelboraf for melanoma, Novartis's Cosentyx for psoriasis and Takeda's gastrointestinal P-CAB inhibitor Takecab clears the way for the products’ commercial launch in the country.

Most of the newly priced products were granted formal approval at the end of last year ([A#28141228003]), and will be added to the national health insurance system reimbursement tariff on Feb.24.

Many products are launched on the same day as the listing.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Japan

More from Focus On Asia

BlissBio Goes Solo On HER2-Targeting ADC After Eisai Exit

 
• By Dexter Jie Yan

BlissBio is to single-handedly move BB-1701, its eribulin-containing, HER2-targeting antibody-drug conjugate, into a global pivotal Phase II/III program for HER2-expressing, Enhertu-resistant breast cancer.

Watch This Space: Miltenyi‘s ‘Brain-To-Vein,’ Point-Of-Care CAR-T Efforts In India

 
• By Anju Ghangurde

From a letter of intent with BIRAC sealed at BIO 2025 to supporting Immuneel’s CAR-T efforts and a study for point-of-care manufactured anti-CD19 CAR-T cell therapy, Miltenyi Biotec is moving on multiple fronts in India. The German group also expects to advance its own CAR-T candidates.

Global Pharma Interest In Korea Undeterred Despite Political Roller Coaster

 
• By Jung Won Shin

Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.